Emtora Biosciences: Funding, Investors & Team (Sep 2026)
Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug. The company developing a novel formulation of rapamycin, eRapa for use in preventing the onset and recurrence of cancer. It manufactures a drug to slow the aging process and its efficacy in treating age-related diseases. The eRapa is the only pharmaceutical agent to demonstrate significantly increased healthspan and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.
Emtora Biosciences has raised $16.9M across 1 funding round on record, the most recent a Grant of $16.9M announced in Aug 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Emtora Biosciences Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Emtora Biosciences Funding Rounds
Emtora Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Emtora Biosciences Funding Compared to Other Biotechnology Startups
Emtora Biosciences' latest round of $16.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Emtora Biosciences in Biotechnology and San Antonio
Companies Similar to Emtora Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Emtora Biosciences Funding FAQs
What does Emtora Biosciences do?
Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug. The company developing a novel formulation of rapamycin, eRapa for use in preventing the onset and recurrence of cancer. It manufactures a drug to slow the aging process and its efficacy in treating age-related diseases. The eRapa is the only pharmaceutical agent to demonstrate significantly increased healthspan and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.
How much funding has Emtora Biosciences raised?
Emtora Biosciences has raised $16.9M across 1 round on record. The most recent is a Grant of $16.9M announced in Aug 2022.
When did Emtora Biosciences last raise funding?
Emtora Biosciences' most recent funding round on record is a Grant of $16.9M, announced in Aug 2022.
Who is the CEO of Emtora Biosciences?
Dan Hargrove is listed as CEO at Emtora Biosciences.
Where is Emtora Biosciences headquartered?
Emtora Biosciences is based in San Antonio, Texas, United States.
How many employees does Emtora Biosciences have?
Emtora Biosciences is in the 1-10 employee band.
How does Emtora Biosciences' funding compare to other Biotechnology startups?
Emtora Biosciences' latest round of $16.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Emtora Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Emtora Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.